Moderna Abandons CMV Birth Defect Vaccine After Late-Stage Trial Failure

Moderna discontinues its cytomegalovirus vaccine development after Phase 3 trial shows only 6-23% efficacy, missing targets for preventing congenital birth defects in a major setback for the biotech company.